OR WAIT null SECS
The acquisition of Cell Systems will bolster AnaBios’ portfolio of human tissue and cells for use in drug discovery.
AnaBios, a US-based preclinical contract research organization, has acquired Cell Systems, a US-based human primary cell and cell culture media company, in a deal that will bolster AnaBios’ human tissue and cells portfolio. Financial terms of the transaction were not disclosed.
The acquisition will help scientists expedite drug discovery and further understanding of cell biology through access to an expansive array of biologically relevant tools, AnaBios announced in an April 4, 2023 press release.
Cell Systems’ offering includes a variety of human primary cells, including endothelial cells from the brain, liver, kidney, eye, and lung. The company’s liver sinusoidal endothelial cells were used in a recent pivotal study of a novel liver-chip model that was said to have rigorously validated the use of the primary cells for microfluidics application in accordance with industry standards set by the International Consortium for Innovation and Quality in Pharmaceutical Development, according to the press release.
AnaBios’ advanced technologies provide human tissue samples, cells, and services for the pharmaceutical industry and academic laboratories globally. Human primary cells and tissues are important for providing clinically relevant data to increase the success rate of drug development.
“Cell Systems has decades of experience supplying our … human primary cells to pharma/biotech companies and universities around the world that enable translational research using 2D and 3D models, microfluidic devices, and in organ-chip technology. Our primary cells have been instrumental in research of the blood-brain-barrier, liver biology, kidney function, respiratory biology, and much more,” said Jesse Damm, CEO of Cell Systems, in the press release.
“AnaBios is extremely excited to provide Cell Systems’ primary cells to researchers globally and further enhance the landscape of translational research,” said Andre Ghetti, CEO of AnaBios, in the release. “By maximizing the synergies between our offerings and expertise and Cell System’s human primary cells and media, we will provide enhanced translational tools and reagents to academic, pharmaceutical, and biotech researchers and optimize their research programs through enhanced human insights.”